Redwave: the future of blood pressure measurement

Informations projet

Redwave

N° de convention de subvention: 815837

DOI

10.3030/815837

Projet clôturé

Date de signature de la CE 4 Mai 2018

Date de début 1 Juin 2018

Date de fin 30 Novembre 2018

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

REDWAVE MEDICAL GMBH
Germany

Periodic Reporting for period 1 - Redwave (Redwave: the future of blood pressure measurement)

Période du rapport: 2018-06-01 au 2018-11-30

Résumé du contexte et des objectifs généraux du projet

Redwave Medical is a producer of innovative medical algorithms for diagnostic devices in the field of heart and artery diseases. We are focused on central (aortic) blood pressure (cBP) and pulse wave analysis. The project Antares (formerly “Redwave”) is a new oscillometric solution which measures cBP, by combining any regular BP monitor with our new algorithm Antares, which uses the oscillating curves of the BP monitor as input signals without changes in the pumping protocol or in the device hardware. The algorithm is based on the advanced development of Pulse Wave Analysis, a method already used in clinics and specialized practices. Our solution is matching the requirements in robustness and accuracy of the non-controlled environment as it typically exists in homecare measurements. For this reason, it enables the measurement of cBP with home care devices for the first time.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Our main objectives from the grant agreement were to validate and refine our business model, to perform a technology study to assess the technical viability, to complete the market study for identification of potential customers segments in Europe and to plan our communication goals.

We have addressed all four topics by our activities, leading to a completed and improved business plan. Most important, we have reached the first license agreement with a customer and a detailed roadmap to market entry – a clear proof of our business model. Furthermore, technological feasibility has been proven and the algorithm is currently validated in an invasive trial. Additionally, we have established a quality management system, qualifying us as a supplier for medical device manufacturers, and we have developed and follow our patent strategy. We also have completed a market study, with a focus on general market trends, customer segmentation in Europe and competitor analysis. Based on this data, we have planned our upcoming R&D actions to develop the product portfolio and our marketing and communication strategy.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

All in all, as OEM-Software our algorithm will revolutionize hypertension self-monitoring and therapy by the patients – about 85 million people in Europe. The central blood pressure cBP directly affects heart and brain and therefore is directly responsible for heart attacks and strokes, but it differs from the currently measured blood pressure in the arm. By easy and regular measurement of cBP at home, a patient can sustainably reduce the risk and improve hypertension therapy.

Redwave Company Logo